Clinical trials: Stable Schizophrenia
Schizophrenia
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
The purpose of this study was to evaluate the efficacy of ASP4345 on cognitive impairment compared to placebo using change from baseline in MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score (excluding…
- Trial name
- NCT03557931
- Testing
- ASP4345, risperidone, quetiapine
- Where
- 27 sites in United States
- Volunteers
- 233 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Schizophrenia
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
- Trial name
- NCT00977522
- Testing
- PF-03463275
- Where
- 37 sites in United States
- Volunteers
- 207 people
- Sponsor
- Pfizer
Bipolar Disorder, Schizophrenia
A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)
The basic hypothesis of this trial is that forgetfulness and failure to establish a routine that facilitates medication adherence are prominent reasons for non-adherence.
- Trial name
- SEQUEL (NCT00533260)
- Where
- 35 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Schizophrenia
A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.
The purpose of this study is to compare the pharmacokinetics and safety of long-acting injectable risperidone, an atypical antipsychotic medication used for the treatment of patients with schizophrenia, when it is administered as…
- Trial name
- NCT00843687
- Testing
- Risperidone long-acting injectable
- Volunteers
- 188 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia
This open-label, Phase 1 study will investigate the 5-hydroxytryptamine 6 (5-HT6) receptor occupancy in the brain using positron emission tomography (PET) following single oral doses of SLV354.
- Trial name
- NCT01545310
- Testing
- SLV354
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Abbott
Schizophrenia
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia
- Trial name
- NCT01009060
- Testing
- GSK239512
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01716975
- Testing
- EVP-6124
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 767 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms (such as blunted affect, emotional withdrawal, and poor rapport) of schizophrenia.
- Trial name
- NCT00212836
- Testing
- asenapine, olanzapine
- Volunteers
- 481 people
- Sponsor
- Organon and Co
Schizophrenia
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
This is an extension of a previous study (ALK9072-003EXT). The purpose of this study is to continue to evaluate the long-term safety and durability of effect of ALKS 9072 in subjects with stable schizophrenia, and to allow…
- Trial name
- NCT01895452
- Testing
- ALKS 9072, Low Dose, ALKS 9072, High Dose
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 291 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizoaffective Disorder
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients.
- Trial name
- NCT00641745
- Testing
- Lurasidone HCl, Risperidone
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 629 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
The purpose of this study is to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (SGA) in participants with stable…
- Trial name
- NCT02079844
- Testing
- Roflumilast, Second generation antipsychotic
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Takeda
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in psychiatrically stable schizophrenia patients.
- Trial name
- NCT01952132
- Testing
- OMS643762
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Omeros Corporation
Schizophrenia, Schizo-affective Disorder
Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF-02545920 subjects with schizophrenia or schizo-affective disorder who are currently clinically stable and to evaluate the serum and urine pharmacokinetics of…
- Trial name
- NCT00463372
- Testing
- PF-02545920
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- Pfizer
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01714661
- Testing
- EVP-6124
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 753 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Schizoaffective Disorder
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03004 following an escalating single intramuscular injection at 12.5, 25, 37.5, or 50 mg; and to evaluate the safety and tolerability and preliminary…
- Trial name
- LY03004SAD (NCT02055287)
- Testing
- LY03004
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms (such as blunted affect, emotional withdrawal, and poor rapport) of schizophrenia.
- Trial name
- NCT00145496
- Testing
- Asenapine, Olanzapine
- Volunteers
- 468 people
- Sponsor
- Organon and Co
Schizophrenia
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
This clinical study will compare the equivalence of two products containing Paliperidone 100 mg in the form of a prolonged release suspension for injection in patients affected by schizophrenia who are already receiving this…
- Trial name
- NCT03425552
- Testing
- Paliperidone
- Where
- 3 sites in Jordan
- Volunteers
- 70 people
- Sponsor
- Pharmathen S.A.
Schizophrenia
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics (explores what the body does to the drug) of JNJ-37822681 in participants with stable schizophrenia (psychiatric disorder with symptoms of…
- Trial name
- NCT01812642
- Testing
- JNJ-37822681
- Where
- 6 sites in Belgium, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
This is a multiple ascending dose study; the purpose of this study is to examine the safety, tolerability and pharmacokinetics (levels of drug in the blood) of SPD489 in Schizophrenic Patients who are currently maintained on a…
- Trial name
- NCT01457339
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Shire